Lawsuits

Bayer, Janssen settle litigation over blood thinner Xarelto

Bayer has entered into a $775m settlement agreement with Janssen Pharmaceuticals to resolve litigation related with blood thinner medication Xarelto.

FTC, Teva reach global settlement to resolve reverse-payment charges

The US Federal Trade Commission (FTC) and Israel-based Teva Pharmaceuticals Industries have reached a global settlement to resolve three separate federal court antitrust lawsuits involving the latter’s subsidiaries.

US court rejects Indivior’s appeal on Suboxone generic version

The US court has cleared way for Dr. Reddy's Laboratories to launch generic version of Indivior’s Suboxone (buprenorphine and naloxone) sublingual film, which is an opioid addiction treatment.

Pain Therapeutics appeals FDA decision on abuse-deterrent opioid Remoxy

Clinical-stage biopharmaceutical firm Pain Therapeutics has petitioned the Food and Drug Administration (FDA) regarding a complete response Letter (CRL) for Remoxy issued in August this year.

Silence Therapeutics launches interim European injunction application against Alnylam’s Onpattro

Silence Therapeutics has received a notice of intention to grant for a new European divisional patent, EP 3 222 724B, and started a new cross-border interim injunction application in the Netherlands against Alnylam's Onpattro (patisiran).

AHF files review petition with US Supreme Court on Gilead AIDS drug patent case

AIDS Healthcare Foundation (AHF) has filed a petition for writ of certiorari (a petition for review) with the Supreme Court of the US, seeking the Court’s review of the dismissal of a federal lawsuit filed by AHF in January 2016 against Gilead Sciences and other defendants alleging its patent for a key HIV/AIDS drug, tenofovir alafenamide (TAF) is invalid because Gilead manipulated the patent system.

AstraZeneca to pay $110m to settle Texas whistleblower drug lawsuits

AstraZeneca has agreed to pay $110m to settle Texas drugs lawsuit claims of fraudulently marketing Seroquel and Crestor.

Indivior wins US court order blocking Dr. Reddy’s sale of generic opioid treatment

A US court has approved Indivior’s preliminary injunction (PI) preventing Dr. Reddy's Laboratories (DRL) from marketing of generic opioid addiction treatment.

Alnylam signs settlement agreement with Dicerna to resolve trade secret misappropriation claims

Alnylam Pharmaceuticals has entered into a settlement agreement with Dicerna Pharmaceuticals to resolve trade secret misappropriation claims against Dicerna, and counterclaims asserted by Dicerna, in pending litigation in the Superior Court of Middlesex County, Massachusetts.